-+ 0.00%
-+ 0.00%
-+ 0.00%
According to Zhitong Finance App, Beihai Kangcheng-B (01228.HK) announced that Gorenin® (injectable veraginase beta) (Gorenin) and Melibe® (clomaxibat oral solution) (Melibe) have been included in the cost schedule issued by the China Association of Actuaries on November 10, 2026. The cost schedule covers 117 drugs in various treatment fields such as tumors, rare diseases, and chronic diseases, and aims to consolidate the guaranteed pricing foundation for innovative drugs. Both Gorenin and Miley's were selected for this cost schedule, which covered the three rare disease indications of Gaucher disease and Alagerie syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), respectively, which are expected to benefit rare disease groups using commercial insurance channels to reduce the burden of medication use.
Share
Listen to the news
According to Zhitong Finance App, Beihai Kangcheng-B (01228.HK) announced that Gorenin® (injectable veraginase beta) (Gorenin) and Melibe® (clomaxibat oral solution) (Melibe) have been included in the cost schedule issued by the China Association of Actuaries on November 10, 2026. The cost schedule covers 117 drugs in various treatment fields such as tumors, rare diseases, and chronic diseases, and aims to consolidate the guaranteed pricing foundation for innovative drugs. Both Gorenin and Miley's were selected for this cost schedule, which covered the three rare disease indications of Gaucher disease and Alagerie syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), respectively, which are expected to benefit rare disease groups using commercial insurance channels to reduce the burden of medication use.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending